The Patent Finder

Amira Pharmaceuticals, Inc.

18 patents currently held · Updated Nov 18, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 3 name spellings.

10
Ending by 2030
Dec 2029
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 28, 2027
    The maintenance fee for Compounds as lysophosphatidic acid receptor antagonists (US 9,090,573) comes due Jan 28, 2027. Unpaid by Jul 28, 2027, it lapses early.
  • 1 fee due Aug 16, 2027
    The maintenance fee for Heterocyclic autotaxin inhibitors and uses thereof (US 9,260,416) comes due Aug 16, 2027. Unpaid by Feb 16, 2028, it lapses early.
  • 1 fee due Sep 1, 2027
    The maintenance fee for Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis (US 9,272,990) comes due Sep 1, 2027. Unpaid by Mar 1, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 8,048,902Antagonists of lysophosphatidic acid receptors
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,440,707Antagonists of lysophosphatidic acid receptors
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,455,499Alkyne antagonists of lysophosphatidic acid receptors
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,058,300Polycyclic antagonists of lysophosphatidic acid receptors
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,273,780Polycyclic antagonists of lysophosphatidic acid receptors
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,592,402Compounds as lysophosphatidic acid receptor antagonists
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,664,220Polycyclic compounds as lysophosphatidic acid receptor antagonists
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,000,456Polycyclic compounds as lysophosphatidic acid receptor antagonists
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,217,066Compounds as lysophosphatidic acid receptor antagonists
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,624,182Compounds as lysophosphatidic acid receptor antagonists
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 18 patents shown.
Pro members see all 18.
Pro members: see all 18 patents
Also on record, not counted in the 18: 28 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 abandoned · 17 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited